A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Abstract Text:

The toxicity and/or the stimulation of natural killer cell activity that resulted from exposure to alpha-interferon varied according to circadian dosing time, both in mice and in human beings. Ten patients with advanced renal cell carcinoma or melanoma were treated with recombinant alpha-interferon-2b using a continuous 21-day intravenous schedule at circadian modulated rate. Patients received 15-20 MU/m2/day in an ambulatory care program. The drug was delivered via an external programmable-in-time pump. Thirty-nine courses of therapy were given (2-12 courses per patient). Severe side effects included World Health Organization grade III somnolence (one patient, 1 course) and grade III-IV neutropenia (five patients, 10 courses). Karnofsky performance status decreased by 40% in 3 patients (five courses). Two of these patients were withdrawn from the study because of toxicity. Disease was stabilized in four of the seven patients evaluable for response. Seven of the 10 patients are alive at 15 months' median follow-up. Two have continued with chronotherapy for 9+ and 13+ months, respectively. A large interpatient variability characterized the maximally tolerated dose. Two patients led their usual activities while receiving 20 MU/m2/day for three courses or more. Conversely, two patients exhibited severe side effects with 10 MU/m2/day. As compared with schedules of standard administration or continuous flat infusion, this circadian schedule of infusion allowed a large increment in total daily dose and dose intensity. A starting dose of 15 MU/m2/day was well tolerated by 8 of 10 patients and can be recommended using this circadian modulated schedule.

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Publishing Authors By Initials

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of immunotherapy : official journal of the

VOLUME: 10

Page Numbers: 440-7

Journal Abbreviation: J. Immunother.

ISSN: 1053-8550

DAY: 18

MONTH: Dec

YEAR: 1991

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9102704

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: therapy

Chemical & Substance for Abstract: A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients. Information

Substance Name: Interferon Alfa-2b

Registry Number: 99210-65-8

Grant and Affiliation Information for A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.

AFFILIATION: Laboratoire Chronobiologie, Chronopharmacologie and Cancer, SDI CNRS I-6212, Hôpital Paul Brousse, Villejuif, France.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Immunother (1991)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients Related Publications

• A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
• Effect of (18)F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer.